TAT 2016
 
Monday, March 21, 2016
9:00 am - 10:15 amPlenary Session 1: Opening Ceremony
Chair: Jean-Pierre Armand, Cancer Institute Gustave Roussy
Chair: Giuseppe Giaccone, Georgetown University
9:01 am - 9:08 amOpening address
Speaker: Giuseppe Giaccone, Georgetown University
9:08 am - 9:15 amOpening address
Speaker: Louis Weiner, Georgetown University - LCCC
9:15 am - 9:45 amO1.1 TAT 2016 Honorary Award Lecture: Disrupting Early Clinical Trials
Speaker: Anthony Tolcher, South Texas Accelerated Research Therapeutics
9:45 am - 10:15 amO1.2 Keynote lecture: Rational combinations of immunological, targeted and chemotherapeutic agents and the implementation of immunotherapy in targeted treatment strategies
Speaker: Laurence Zitvogel, Cancer Institute Gustave Roussy
10:15 am - 10:40 amBreak




10:40 am - 12:00 pmPlenary Session 2: Immuno-oncology (1)
Chair: Michael Atkins, Geogetown-Lombardi Comprehensive Cancer Center
Chair: Gail Eckhardt, University of Colorado Cancer Center
10:41 am - 11:00 amO2.1 Predictive biomarkers (positive and negative) for immunological agents
Speaker: Janis Marie Taube, The Johns Hopkins Hospital
11:00 am - 11:20 amO2.2 Tumor genomics and response to immunotherapy
Speaker: Matthew Hellmann, Memorial Sloan Kettering Cancer Center
11:20 am - 11:40 amO2.3 The microbiome and cancer therapy
Speaker: Giorgio Trinchieri, National Cancer Institute
11:40 am - 12:00 pmGeneral discussion
12:00 pm - 1:00 pmLunch & Poster viewing


1:00 pm - 2:30 pmPlenary Session 3: Phase 1 Studies - Completed or in Progress (miscellaneous drugs & targets)
Chair: Lesley Seymour, Queen's University
Chair: Shivaani Kummar, Stanford University Cancer Institute
1:01 pm - 1:15 pmO3.1 A first in human study of the dual ROCK I/II inhibitor AT13148 in patients with solid tumours
Speaker: Udai Banerji, The Institute of Cancer Research
1:15 pm - 1:30 pmO3.2 A Phase I/II and PK/PD Study of ASN002, a Potent Dual SYK/JAK Inhibitor, in Patients with Advanced Solid Tumors and B-Cell Lymphomas
Speaker: Drew Rasco, South Texas Accelerated Research Therapeutics
1:30 pm - 1:45 pmO3.3 Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors
Speaker: Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori
1:45 pm - 2:00 pmO3.4 Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
Speaker: Christophe Massard, Cancer Institute Gustave Roussy
2:00 pm - 2:15 pmO3.5 A Phase 1a/b Study of OMP-131R10, an Anti-RSPO3 Antibody, in Advanced Solid Tumors and Previously Treated Metastatic Colorectal Cancer
Speaker: Gail Eckhardt, University of Colorado Cancer Center
2:15 pm - 2:30 pmO3.6 A first-in-human first-in-class trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours
Speaker: Ruth Plummer, Newcastle University
2:30 pm - 2:55 pmBreak


2:55 pm - 4:35 pmPlenary Session 4: New Drugs and Targets in Hemato-Oncology
Chair: Yves Pommier, National Cancer Institute
Chair: Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori
2:56 pm - 3:15 pmO4.1 Targeting intracellular pathways in chronic lymphocytic leukemia
Speaker: Jennifer Woyach, The Ohio State University 
3:15 pm - 3:35 pmO4.2 Monoclonal antibody based strategies in acute leukemia: emphasis on bi-specific antibodies
Speaker: Farhad Ravandi, The University of Texas MD Anderson Cancer Center
3:35 pm - 3:55 pmO4.3 Chimeric Antigen Receptor (CAR)-modified T cell therapy in hematologic malignancies
Speaker: David L. Porter, University of Pennsylvania
3:55 pm - 4:10 pmGeneral discussion
4:10 pm - 4:40 pmKeynote Lecture: Genomic analysis and targeted therapy of lung cancers
Speaker: Matthew Meyerson, Dana-Farber Cancer Institute


Special Sumposium (non-CME)
4:45 pm - 5:45 pmSpecial Symposium (non-CME) Immuno-Oncology and Third-Generation Tyrosine Kinase Inhibitors Company Updates
Chair: Hilary Calvert, UCL Cancer Institute
Chair: Jean-Pierre Armand, Cancer Institute Gustave Roussy
4:46 pm - 5:00 pmIMMUNE CHECKPOINT BLOCKADE CLINICAL THERAPY.. AND BEYOND
Speaker: Suba Krishnan, Bristol-Myers Squibb
5:00 pm - 5:15 pmPERSONALIZED APPROACHES TO COMBINATION IMMUNOTHERAPY
Speaker: Carol O’Hear, Genentech
5:15 pm - 5:30 pmMK-6018: A NOVEL IMMUNE CHECKPOINT INHIBITOR TARGETING CEACAM1
Speaker: Archie N. Tse, Merck & Co
5:30 pm - 5:45 pmBI 1482694: A THIRD GENERATION (MUTANT SPECIFIC) EGFR TKI
Speaker: William F. Goeckeler, Boehringer Ingelheim Pharmaceuticals
6:00 pm - 7:00 pmPoster Viewing & Welcome Reception